This HTML5 document contains 183 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1159/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q49658111
rdf:type
wikibase:Item
schema:description
tudományos cikk article scientific teaduslik artikkel научная статья articol științific article scientifique scientific article published on 13 December 2017 2017年学术文章 2017年学术文章 artykuł naukowy מאמר מדעי บทความทางวิทยาศาสตร์ 2017年學術文章 2017年學術文章 2017 nî lūn-bûn 2017年學術文章 επιστημονικό άρθρο scientific article published on 13 December 2017 vitskapeleg artikkel vetenskaplig artikel wetenschappelijk artikel ১৩ ডিসেম্বর ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artikulong pang-agham vitenskapelig artikkel научна статия 2017年学术文章 artigo científico 2017年學術文章 научни чланак scientific article published on 13 December 2017 სამეცნიერო სტატია 2017年学术文章 artigo científico 2017年學術文章 scienca artikolo مقالة علمية نشرت في 13 ديسمبر 2017 videnskabelig artikel articolo scientifico bilimsel makale наукова стаття, опублікована в грудні 2017 artikull shkencor 2017年学术文章 artículo científico publicado en 2017 2017年の論文 wissenschaftlicher Artikel bài báo khoa học tieteellinen artikkeli vedecký článok vědecký článek article científic научни чланак 2017年学术文章 naučni članak artigo científico artículu científicu 2017년 논문 artikel ilmiah мақолаи илмӣ
p:P577
wds:Q49658111-C857DAC5-5640-4373-BE16-F1D5B3CE6C25
wdt:P577
2017-12-13T00:00:00Z
p:P2860
wds:Q49658111-BED55581-35C9-4838-8AA0-25D7533CBC13 wds:Q49658111-C9168E5F-1B5C-4D99-B121-3C756A6E6CE9 wds:Q49658111-B2C699FD-BD93-4036-A856-B6550F984C00 wds:Q49658111-B64A3992-45C3-49B9-95DF-902DE3A2E709 wds:Q49658111-8BF85C0C-F606-4CE9-9442-4DB9C26C8602 wds:Q49658111-8CFB3E3F-25AD-4754-AF19-4A020C106FBC wds:Q49658111-AF21936A-2175-4C68-8455-084ED64C084E wds:Q49658111-816DC425-03FC-4B61-8612-30F4F55941E6 wds:Q49658111-82E5B5FE-02AF-4597-8628-E054236514E4 wds:Q49658111-830F8506-21EF-4243-ADA9-06EEFE1ECFB7 wds:Q49658111-5FC791E3-730B-47C3-A7F3-973AF9255858 wds:Q49658111-4F21ADE9-F749-4CF6-BF30-E1A02CF449D1 wds:Q49658111-5127204B-F962-42B6-B999-A0A84FB5B680 wds:Q49658111-58E1B27B-A5D2-41B5-BB1F-DEEA1D0F1975 wds:Q49658111-394196E8-210E-43F9-B5F3-C60D4CD02FD5 wds:Q49658111-35FF7D5C-48BF-48D6-9696-10BAD017705D wds:Q49658111-3649103C-C757-458C-8535-BEE3E86B6912 wds:Q49658111-F7E6BC24-A3FF-44E4-8F05-6397B5FABB72 wds:Q49658111-E30DBAEA-EA19-449C-B9BD-3A6492631CF0 wds:Q49658111-27FA8489-2E06-4A41-B8E3-5224B3E7BAAE wds:Q49658111-32838118-8133-4421-B0F5-9E4FA855A982 wds:Q49658111-18E4E655-D50C-4E99-8809-99C0FFB2BB07 wds:Q49658111-19B69393-B5D8-4A2E-B32A-5D61DC4E923D wds:Q49658111-0A8C8387-60ED-4D30-B978-AE6C39BAE3FA wds:Q49658111-04DBEDC5-3B61-44D7-9C4A-356419991DF8
wdt:P2860
wd:Q35578249 wd:Q53150011 wd:Q47134445 wd:Q41931102 wd:Q38439475 wd:Q34782523 wd:Q40972293 wd:Q29615215 wd:Q27468570 wd:Q30961976 wd:Q86692459 wd:Q41039957 wd:Q35973246 wd:Q38573559 wd:Q38383470 wd:Q38380470 wd:Q33835824 wd:Q53084508 wd:Q28188162 wd:Q57312402 wd:Q38729780 wd:Q36431670 wd:Q59745749 wd:Q34673134 wd:Q39510234
p:P2093
wds:Q49658111-F53ABBC3-C9A0-4C79-B853-E7A853D478DB wds:Q49658111-CAC703F3-9E06-432A-B34B-71FB68CC7403 wds:Q49658111-F41CF346-A5C4-464B-AA26-6FC72C8429B0 wds:Q49658111-EC3985FE-53B7-48DC-B5EB-31B7D2036057 wds:Q49658111-EF212BCB-2591-4065-AF94-AA5679A56B53 wds:Q49658111-6C8FEE18-DFB5-4424-8E4D-5BF88AC6E3EA wds:Q49658111-6E0961D2-79C2-4CBA-AD04-9CB66E776FB1 wds:Q49658111-6394925E-7DAB-4F97-BACE-CE7E163343A3 wds:Q49658111-37D010AB-0C5E-4738-BA64-30294F83DCB4 wds:Q49658111-36488CCF-9B34-43C7-BB16-069455246606 wds:Q49658111-489F1E54-F96E-45BF-B764-9E1BAABFBFE7 wds:Q49658111-3B090377-29F6-4DC7-B301-7A364DD5253A wds:Q49658111-8CD2C9B4-1ECE-4259-A81E-D0E238EDE1B5 wds:Q49658111-11F487C0-08BA-4F2F-8BE0-BDE80052EA2A wds:Q49658111-122FA97F-DDD0-4A07-9196-14BF25FA2CEB wds:Q49658111-33EC1CF6-A3B5-49BF-ACFA-B794950EB948 wds:Q49658111-0359B0A8-AF61-4B24-B6B8-071679630930 wds:Q49658111-0E314654-FCF8-4537-949D-2BEE1258EF51 wds:Q49658111-1123D119-ED68-46D9-B734-640C19EEB3E8
wdt:P2093
David M Charytan Scott Bull Robert Edwards Vlado Perkovic George L Bakris Barry M Brenner Meg J Jardine Bruce Neal Hong Zhang CREDENCE study investigators Hiddo J L Heerspink Adeera Levin Tom Greene David C Wheeler Dick de Zeeuw Mehul Desai Carol Pollock Rajiv Agarwal John Xie
rdfs:label
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
skos:prefLabel
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
schema:name
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
p:P50
wds:Q49658111-00AB39E0-22C5-4FDD-B597-E233296FC8FE wds:Q49658111-07934C10-827D-497F-925A-870820362D78 wds:Q49658111-0A972402-287B-4010-8B34-28BFF86E18C8
wdt:P50
wd:Q90608635 wd:Q61337175 wd:Q63101609
p:P1476
wds:Q49658111-F0E6C093-9ACE-458F-BFA4-5735CFA4ACC5
wdt:P1476
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
p:P304
wds:Q49658111-DF9DABB8-718D-4CB7-BD09-5EEB58CE04F7
wdt:P304
462-472
p:P31
wds:Q49658111-C54BE9B6-0C53-4BAB-8AFE-3D73368B4675
wdt:P31
wd:Q13442814
p:P921
wds:Q49658111-42755EB3-67BD-4DEA-8E8F-E75A85B651D7
wdt:P921
wd:Q1054718
p:P698
wds:Q49658111-B8F8DCEA-303F-4243-B346-D5F2FA97973E
wdtn:P698
n11:29253846
wdt:P698
29253846
p:P1433
wds:Q49658111-8356F4B8-5D7D-431E-8C4C-3C43CE815110
wdt:P1433
wd:Q15762667
p:P433
wds:Q49658111-58E8E0C7-EB7E-4C51-8E5F-992B195905C3
p:P478
wds:Q49658111-1CD0FF43-4112-41F8-8001-31A775B60777
wdt:P433
6
wdt:P478
46
p:P356
wds:Q49658111-CD929CF8-38B0-43EF-B059-7DD167827C4E
wdtn:P356
n12:000484633
wdt:P356
10.1159/000484633
p:P932
wds:Q49658111-AFAE9AAD-DEF2-419E-999C-1C0FA17A81E0
wdt:P932
5804835